ArsenOsipovMD

Oncology • West Hollywood, CA

Gastrointestinal Cancer

Chief Medical Oncology Fellow

Join to view full profile

Dr. Osipov is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Osipov's full profile

Already have an account?

Office
8700 Beverly Blvd
West Hollywood, CA 90048
Phone+1 310-423-6066

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2017 - 2020
Cedars-Sinai Medical CenterResidency, Internal Medicine, 2013 - 2016
Virginia Commonwealth University School of MedicineClass of 2013

Certifications & Licensure

CA State Medical License 2015 - 2027
MD State Medical License 2017 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma Start of enrollment: 2019 Jun 04
Recruiting
Phase 2
Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma Start of enrollment: 2021 Jul 28
Active, not recruiting
Phase 2

Publications & Presentations

PubMed

124 citations
Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death.
Kazukuni Hayashi, Fotis Nikolos, Y. C. Lee, Antrix Jain, Efrosini Tsouko
Nature Communications. 2020-12-07
6 citations
Nanoprodrugs of NSAIDs: Preparation and Characterization of Flufenamic Acid Nanoprodrugs
Bong Seop Lee, Chi Woo Yoon, Arsen Osipov, Nuriel Moghavem, Daniel Nwachokor
Journal of Drug Delivery. 2011-04-05

Lectures

Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Theriva Biologics to Host Key Opinion Leader Webinar on Lead Program, VCN-01 and Advancing Unique Oncolytic Virus TherapeuticsOctober 31st, 2022
Can You Get Two Cancers at the Same Time?October 7th, 2022
Three-Step Treatment Strategy for Pancreatic CancerJuly 8th, 2022
Join now to see all